{
    "clinical_study": {
        "@rank": "154780", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Active Comparator", 
                "description": "Intravitreal administration of ranibizumab (either 0.3 or 0.5 mg, given monthly, as detailed in the prescribing information and label content approved for the country governing the study site) plus an oral placebo."
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "Oral PF-04634817 200 mg, once daily plus a masked sham therapy (given monthly)."
            }
        ], 
        "brief_summary": {
            "textblock": "The study hypothesis under test is that administration of the CCR2/5 antagonist has the\n      potential to be as effective as the current treatment options for subjects with diabetic\n      macular edema. The current treatment option for these subjects is an injection directly into\n      the eye, while this CCR2/5 antagonist would be an oral drug which has the potential to be\n      just as effective. This CCR2/5 antagonist also has a broader anti-inflammatory potential and\n      might be able to provide an alternative mechanism to treat Diabetic Macular Edema."
        }, 
        "brief_title": "A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Macular Edema, Diabetic", 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with Diabetes Mellitus (Type 1 or Type 2) Showing Diabetic Macular Edema in\n             the Eye\n\n          -  Reduced visual acuity resulting from retinal thickening\n\n          -  Female subjects of non-childbearing potential \u226518 years and male subjects greater\n             than or equal to 18 years. A subject is of childbearing potential if, in the opinion\n             of the investigator, he/she is biologically capable of having children and is\n             sexually active.\n\n          -  Female subjects who are not of childbearing potential must meet at least one of the\n             following criteria:\n\n               -  Have undergone a documented hysterectomy and/or bilateral oophorectomy;\n\n               -  Have medically confirmed ovarian failure; or\n\n               -  Achieved post-menopausal status, defined as: cessation of regular menses for at\n                  least 12 consecutive months with no alternative pathological or physiological\n                  cause; and have a serum follicle stimulating hormone (FSH) level within the\n                  laboratory's reference range for postmenopausal females.\n\n        Exclusion Criteria:\n\n          -  Severe Impaired Renal Function\n\n          -  Any intraocular condition or previous surgery in either eye that would likely require\n             medical or surgical intervention during the study duration or if allowed to progress\n             untreated for the 16 weeks of study duration, would likely contribute to a reduction\n             in visual acuity."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01994291", 
            "org_study_id": "B1261009"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 1", 
                "description": "Intravitreal Injection supplied as:\n10 mg/mL in a 0.2 mL vial with instructions on preparation and administration of the 0.5 mg (0.05 mL) dose.\n6 mg/mL in a single use vial with instructions on preparation and administration of the 0.3 mg (0.05 mL) dose.\nAdminstered once a month for 12 weeks", 
                "intervention_name": "Ranibizumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 1", 
                "description": "Oral Placebo is provided in tablet form to match the 50mg dose of PF-04634817.\nDose is 4 tablets each day for 12 weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "description": "Four 50mg tablets PF-04634817 once a day for 12 weeks.", 
                "intervention_name": "PF-04634817", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "description": "Empty, needle-less syringe is used by the unmasked team once a month.", 
                "intervention_name": "Masked Sham Therapy", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chemokine Antagonist", 
            "Diabetic Macular Edema", 
            "Diabetes", 
            "Diabetes Mellitus", 
            "Macular Edema", 
            "Diabetic Retinopathy", 
            "Anti-VEGF"
        ], 
        "lastchanged_date": "May 9, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1261009&StudyName=A%20Phase%202%2C%20Multi-Center%20Study%20To%20Compare%20The%20Efficacy%20And%20Safety%20Of%20A%20Chemokine%20CCR2/5%20Receptor%20Antagonist%20With%20Ranibizumab%20In%20Adult"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85207"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85014"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85704"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beverly Hills", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90211"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palm Desert", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92211"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winter Haven", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33880"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Augusta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30909"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46290"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jackson", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "49202"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28210"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44122"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73104"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Mifflin", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15122"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rapid City", 
                        "country": "United States", 
                        "state": "South Dakota", 
                        "zip": "57701"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78705"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78240"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chisinau", 
                        "country": "Moldova, Republic of", 
                        "zip": "2025"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Moldova, Republic of"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist (PF-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean Change from Baseline in the Best Corrected Visual Acuity Score", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01994291"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of participants gaining 15 ETDRS letters in BCVA from baseline", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 Weeks"
            }, 
            {
                "measure": "Mean changes in central subfield retinal thickness from baseline as assessed by optical coherence tomography (OCT)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 Weeks"
            }, 
            {
                "measure": "Mean changes in the area of fluorescein leakage from baseline by scheduled study visit as assessed by fluorescein angiography (FA)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 Weeks"
            }, 
            {
                "measure": "Mean change in steps of diabetic retinopathy (ETDRS severity scale) from baseline as assessed by digital fundus photography (FP)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 Weeks"
            }, 
            {
                "description": "PK samples will be taken pre-dose and 2 hours (+15 mins) post-dose for all randomized subjects from Visit 2 to Visit 4 and during Visit 5. The systemic exposure of PF-04634817 will be evaluated at the above mentioned time points. Summary statistics for exposure at different time points will be presented.", 
                "measure": "The systemic exposure of PF-04634817 in participants with diabetes and macular edema", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}